drugset / Trial / NCT00719823

Maraviroc Compassionate Use

NCT00719823

Phase 3 Withdrawn ViiV Healthcare Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to provide Maraviroc on a compassionate use basis to antiretroviral treatment experienced patients infected with CCR5-tropic HIV-1 with urgent unmet medical needs and who, in the opinion of the physician, require Maraviroc to form a viable regimen.

Timeline

Start
2008-08
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg Oral
Subject Maraviroc Other / unclassified 300 mg Oral
Subject Maraviroc Other / unclassified 600 mg Oral